<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02788071</url>
  </required_header>
  <id_info>
    <org_study_id>H-15016343</org_study_id>
    <nct_id>NCT02788071</nct_id>
  </id_info>
  <brief_title>Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome</brief_title>
  <official_title>Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome (IBS) - a Randomized, Double-blind Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aleris-Hamlet Hospitaler København</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aleris-Hamlet Hospitaler København</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if fecal microbiota transplantation (FMT) will&#xD;
      result in improvement in clinical outcome in patients with irritable bowel syndrome (IBS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irritable bowel syndrome (IBS) is the most commonly diagnosed gastrointestinal condition. IBS&#xD;
      is associated with a high use of health-care costs and can substantially reduce quality of&#xD;
      life and work productivity.&#xD;
&#xD;
      Several studies have demonstrated that the composition of the gut microbiota in IBS patients&#xD;
      is different from healthy controls.&#xD;
&#xD;
      Fecal microbiota transplantation (FMT) could therefore be a treatment option for IBS patients&#xD;
      by exchanging the microbiota of an IBS patient with the microbiota of a healthy donor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptoms score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by the Irritable bowel syndrome - severity symptom score (IBS-SSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota diversity</measure>
    <time_frame>Day 4, 4 weeks, 12 weeks and 24 weeks</time_frame>
    <description>Measured by DNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota diversity IBS patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota diversity in healthy donors</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DNA sequencing. To compare with the recipients (IBS patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Irritable Bowel Syndrome-Quality of Life (IBS-QOL) Questionnaire Scores</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>FMT capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMT placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FMT capsules</intervention_name>
    <description>25 capsules per day for 12 days</description>
    <arm_group_label>FMT capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FMT placebo</intervention_name>
    <description>25 capsules per day for 12 days</description>
    <arm_group_label>FMT placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfilled Rome III diagnostic criteria for IBS&#xD;
&#xD;
          -  Moderate-severe disease activity (IBS-Symptom Severity Score ≥175)&#xD;
&#xD;
          -  Able to read and speak Danish&#xD;
&#xD;
          -  Normal colonoscopy at age ≥ 40 years (performed within 1 year) or blood in stool&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other chronic gastrointestinal disease&#xD;
&#xD;
          -  Positive fecal sample with enteropathogenic microorganisms or Clostridium difficile&#xD;
&#xD;
          -  Positive screening for HIV, Hepatitis B or HCV antibody&#xD;
&#xD;
          -  Surgical interventions in the gastrointestinal region (except for appendectomy, hernia&#xD;
             repair, cholecystectomy, and gynecological and urological procedures)&#xD;
&#xD;
          -  Psychiatric disorder&#xD;
&#xD;
          -  Fecal calprotectin ≥ 50 mg/kg&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Medications other than birth control pills, hormone supplements, allergies and asthma&#xD;
             agents, blood pressure and cholesterol lowering agents, proton pump inhibitors and&#xD;
             non-prescription medicines&#xD;
&#xD;
          -  Abnormal screening biochemistry&#xD;
&#xD;
          -  Abnormal colonoscopy findings&#xD;
&#xD;
          -  Pregnant, planned pregnancy or breastfeeding females&#xD;
&#xD;
          -  Ingestion of probiotics or antibiotics &lt; 8 weeks before the inclusion&#xD;
&#xD;
        Inclusion criteria for donors&#xD;
&#xD;
          -  Age between 18-45 years&#xD;
&#xD;
          -  Past and current healthy&#xD;
&#xD;
          -  Normal weight (BMI between 18,5-24,9 kg/m2)&#xD;
&#xD;
          -  Normal bowel movements (defined as 1-2 per day and type 3-4 at Bristol Stool Form&#xD;
             Scale)&#xD;
&#xD;
          -  No medication consumption&#xD;
&#xD;
        Exclusion criteria for donors&#xD;
&#xD;
          -  Known or high risk of infectious diseases such as HIV, hepatitis A, B or C&#xD;
&#xD;
          -  Positive stool sample for C. difficile toxin, parasites or other pathogens&#xD;
&#xD;
          -  Antibiotic treatment in the past 6 months&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Tattoo or body piercing within the last 6 months&#xD;
&#xD;
          -  Allergy, asthma or eczema&#xD;
&#xD;
          -  Family history of gastrointestinal diseases&#xD;
&#xD;
          -  Participation in high-risk sexual behaviors&#xD;
&#xD;
          -  Born by Caesarean section&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Højer Christensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aleris-Hamlet Hospitaler København</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aleris Hamlet Hospitaler, København</name>
      <address>
        <city>Copenhagen</city>
        <state>Søborg</state>
        <zip>2760</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>May 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aleris-Hamlet Hospitaler København</investigator_affiliation>
    <investigator_full_name>Alice Højer Christensen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

